DeGregorio Mw

No ORCID on file · 2 papers in corpus

2017

Repurposing ospemifene for potentiating an antigen-specific immune response.

Menopause (New York, N.Y.) ·doi:10.1097/gme.0000000000000776

ObjectiveOspemifene, an estrogen receptor agonist/antagonist approved for the treatment of dyspareunia and vaginal dryness in postmenopausal women, has potential new indications as an immune modulator. The overall objective of the present s…

article 2013

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

Lin H Soe, Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA, USA Abstract: Ospemifene is a selecti…